专科用药
专科用药是指针对特定疾病或系统性疾病开发的药物，通常具有明确的作用靶点和治疗目标。这类药物在研发过程中需要经过严格的临床试验验证其安全性和有效性。以下是几种常见的专科用药类别及其应用领域：
- 抗感染药：包括抗生素、抗病毒药等，用于治疗细菌、病毒引起的感染疾病。
- 心血管系统用药：如降压药、抗心律失常药、调脂药等，针对心脏和血管系统的疾病进行治疗。
- 神经系统用药：包括镇痛药、抗抑郁药、抗精神病药等，用于缓解或治疗各种神经系统相关的症状和疾病。
- 内分泌系统用药：如胰岛素、甲状腺激素等，用于调节人体内的激素水平。
- 肿瘤用药：通过不同的机制对抗癌症，包括化疗药物、靶向治疗药物及免疫治疗药物。
- 呼吸系统用药：如支气管扩张剂、吸入性皮质激素等，针对肺部疾病提供支持和治疗。
专科用药的研发需要依据药物化学的基本原理设计和合成化合物，并通过药理学、毒理学以及临床前研究来评估其潜在的疗效与安全性。此外，在药物上市之前还须经过严格的临床试验以确保药物对患者的安全性和有效性。
| 中文名称 | 英文名称 | CAS号 | 化学式 | 结构式图片 |
|---|---|---|---|---|
| —— | Caspo | 162808-62-0 | C52H88N10O15 |
|
| —— | l-HMPAO | 105613-48-7 | C13H28N4O2 |
|
| —— | N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-3-[(1R)-3-amino-1-hydroxypropyl]-21-[(2-aminoethyl)amino]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-10,12-dimethyltetradecanamide | 179463-17-3 | C52H88N10O15 |
|
| —— | (5Z,7E,22E)-(1S,3R,24S)-1,3,24-trihydroxy-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene | 112965-21-6 | C27H40O3 |
|
| —— | acetic acid;N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide | 179463-17-3 | C56H96N10O19 |
|
| —— | (3S,4aS,8aS)-N-tert-Butyldecahydro-3-isoquinolinecarboxamide | 136465-81-1 | C14H27N2O+ |
|
| —— | (5Z,7E,20S,22E,24R)-24-cyclopropyl-9,10-secocholester-5,7,10(19),22-tetraene-1α,3β,24-triol | 112965-21-6 | C27H40O3 |
|
| —— | Methyl cellulose | 9004-67-5 | C20H38O11 |
|
| —— | Wln: AL2 S-O4*3 | 10043-01-3 | AlH2O4S |
|
| —— | 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 | 162808-62-0 | C52H88N10O15 |
|
| —— | Caspofungin (Acetate) | 179463-17-3 | C56H96N10O19 |
|
| —— | acetic acid;(10S,12R)-N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide | 179463-17-3 | C56H96N10O19 |
|
| —— | Dicopper citrate | 866-82-0 | C6H4Cu2O7 |
|
| —— | Caspofungin | 162808-62-0 | C52H88N10O15 |
|
| —— | Duract | 120638-55-3 | C15H13BrNNaO4 |
|
| —— | 1-Methyl-2-(nitrosomethylidene)-1,2-dihydropyridine--hydrogen iodide (1/1) | 94-63-3 | C7H9IN2O |
|
| —— | (5E)-5-[(2E)-2-[1-[(E)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol | 112965-21-6 | C27H40O3 |
|
| —— | Zinc Oxide | 55204-38-1 | OZn |
|
| —— | (1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-5-cyclopropyl-5-hydroxypent-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol | 112965-21-6 | C27H40O3 |
|
| —— | naltrexone hydrochloride | 16590-41-3 | C20H23NO4 |
|
| —— | acetic acid;(10R,12S)-N-[(3S,9S,11R,18S,20R,21R,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide | 179463-17-3 | C56H96N10O19 |
|
| —— | N-[(6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide | 162808-62-0 | C52H88N10O15 |
|
| —— | N-[(3S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide | 166663-25-8 | C58H73N7O17 |
|
| —— | sodium cacodylate | 124-65-2 | C2H6AsO2*Na |
|
| —— | cancidas | 162808-62-0 | C52H88N10O15 |
|
| —— | naloxone hydrochloride | 357-08-4 | C19H21NO4*ClH |
|
| —— | (S)-(+)-allantoin | 3844-67-5 | C4H6N4O3 |
|
| —— | naloxone | 465-65-6 | C19H21NO4 |
|
| —— | unithiol | 4076-02-2 | C3H7O3S3*Na |
|
| —— | Glc2Me3Me4Me6Me(b1-4)b-Man1Me2Me3Me6Me | 9004-67-5 | C20H38O11 |
|
| —— | zinc oxide | 1314-13-2 | HOZn |
|
| —— | succimer | 304-55-2 | C4H6O4S2 |
|
| —— | toxogonin | 114-90-9 | C14H16N4O3*2Cl |
|
| —— | pralidoxime iodide | 94-63-3 | C7H9N2O*I |
|
| —— | (7Ξ,9Ξ,11<i>E</i>,13Ξ)-retinoic acid | 302-79-4 | C20H28O2 |
|
| —— | retinoic acid | 302-79-4 | C20H28O2 |
|
| —— | naltrexone hydrochloride | 465-65-6 | C19H21NO4 |
|
| —— | glutathion | 70-18-8 | C10H17N3O6S |
|
| —— | N-[6-[1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis(1-hydroxyethyl)-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide | 166663-25-8 | C58H73N7O17 |
|
| —— | naltrexone | 16590-41-3 | C20H23NO4 |
|
联系我们
关注我们
公众号
